On May 14, 2025 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, reported new preclinical data from its INB-619 program at the 2025 American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting (Press release, In8bio, MAY 14, 2025, View Source [SID1234653060]). The data shows that INB-619, a CD-19 targeted γδ TCE, successfully eliminated disease-causing B cells in blood samples from patients with active Systemic Lupus Erythematosus (SLE, or Lupus).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These findings highlight the potential of INB-619 as a novel treatment option for autoimmune diseases, where harmful B cells secrete antibodies that drive inflammation and tissue damage. Unlike traditional TCEs that target CD3 and can often trigger severe side effects, INB-619 harnesses the unique properties of γδ T cells to selectively clear B cells while minimizing inflammatory responses.
William Ho, Chief Executive Officer of IN8bio, commented, "Our findings show that INB-619 not only eliminates pathogenic B cells, but also expands γδ T cell levels, which are often reduced in patients with chronic disease. This represents a fundamentally different approach to immune modulation – one that could potentially lead to safer, more effective treatments for autoimmune diseases and beyond."
Highlights from the Preclinical Data:
INB-619 demonstrated complete, targeted depletion of B cells in lupus patient-derived samples.
IN8bio’s γδ TCE successfully expands both Vδ1+ and Vδ2+ subtypes of γδ T cells, which are critical for targeting both circulating and tissue-resident B cells to potentially achieve deeper B cell depletion.
Unlike conventional CD3-based TCEs, INB-619 did not trigger significant release of inflammatory cytokines such as IL-6, which are commonly associated with serious toxicities, including CRS.
The study reinforces the potential of γδ T cell engagers as a safer, more precise immunotherapy platform for autoimmune diseases.
With these encouraging results, IN8bio continues to explore potential partnerships and additional autoimmune and cancer indications where γδ T cell biology and B cell targeting intersect.